Gene therapy shows promise in tackling X-linked RP
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
Search results
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
Join us for our upcoming webinar!
Russ was diagnosed with Choroideremia at the age of 11, after visiting caves in Spain and not being able to see anything.
Join thousands of runners in chasing a personal best, whilst supporting Retina UK and start and finish in the Molineux Stadium.
Walk, jog or run this wonderful route along the River Thames. There are 100km, 50km and 25km challenge options.
Listen to our webinar to hear about our Information and Support Coordinator, Mark Baxter's, holiday in Las Vegas.
Retina UK aims not only to progress research along established threads, but to stimulate new thinking, encourage innovative approaches and nurture original ideas.
Join us for an inspiring webinar where young adults living with sight loss share their extraordinary stories and insights.
In February 2022, ProQR announced a disappointing outcome for their phase 2/3 trial of sepofarsen for Leber congenital amaurosis type 10 (LCA10).
This July, Ben Ramus will lead a group of twelve adventurers as they take on the renowned National Three Peaks Challenge, in aid of national sight loss charity, Retina UK. Ben has decided to take on the epic challenge in recognition of two of his uncles’ sight loss journey, as they live with the rare inherited sight loss condition, retinitis pigmentosa.